Sensorion raises $16m for gene therapies to treat deafness
08 Apr 2024
Gene TherapyClinical StudyCell Therapy
Preview
Source: Pharmaceutical Technology
Mutations in the otoferlin protein are a frequent cause of deafness in children. Image credit: Shutterstock/CC7.
Preview
Source: Pharmaceutical Technology
Sensorion has secured €14.8m ($16m) from its investors to advance its gene therapy programmes for the treatment of deafness and hearing loss disorders.
The capital raise, via the issuance of 24,574,694 shares to existing shareholders, extends the biotech’s cash runway until the end of next year.
The offering is expected to close around 11 April, adding to the private placements of $54m in February 2024 and $38.3m from August 2023.
The France-based biotech stated that the funds will go towards its clinical-stage gene therapy assets indicated for patients with deafness, covering research and development activities through 2025.
See Also:
Pluri launches manufacturing division as cell therapy pipeline progresses
Preview
Source: Pharmaceutical Technology
Navigating post-approval research and reimbursement for orphan therapies
Preview
Source: Pharmaceutical Technology
The biotech said the funds will support the enrolment of the first two cohorts in the trial. The study, called Audiogene, will assess the safety, tolerability, and efficacy of SENS-501 via intra-cochlear injection in paediatric patients with hearing loss.
Sensorion is targeting patients with mutations in the gene coding for otoferlin protein – responsible, amongst other genes, for congenital deafness.
A Sensorion spokesperson told Pharmaceutical Technology that the first results from Audiogene are expected in the second half of 2024.
Also standing to benefit from the financing is the biotech’s second clinical programme for GJB2-GT, a gene therapy designed to restore hearing in those with mutations in the GJB2 gene. This gene encodes for gap junction beta-2 protein, mutated versions of which can cause childhood deafness. Sensorion expects to submit a clinical trial application for the drug in the first half of 2025.
There are currently no approved gene therapies to restore hearing in adults or children, though the research space is ramping up. In January 2024, Eli Lilly subsidiary Akouos reported positive initial data from a Phase I/II trial investigating its gene therapy AK-OTOF for genetic hearing loss. AK-OTOF is also an AAV gene therapy designed to restore hearing in patients with otoferlin gene mutations.
In the same month, a study co-led by Harvard Medical School and Fudan University’s Eye & ENT Hospital in China showed promise with a gene therapy in the same patient population. In February, a gene therapy developed at Italy’s TIGEM Telethon Institute of Genetics and Medicine was used to treat a patient with deafness in the US, as reported by Nature Italy.
Gene therapies are gaining regulatory traction, with 2023 seeing the highest number of approved treatments in the past decade. The global market value of AAV therapies is expected to reach $22.3bn in 2029, up from $1.5bn in 2023, according to analysis by GlobalData.
GlobalData is the parent company of Pharmaceutical Technology.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.